Generation of Induced Neural Stem Cells from Peripheral Mononuclear Cells and Differentiation Toward Dopaminergic Neuron Precursors for Transplantation Studies

Summary

The protocol presents the reprogramming of peripheral blood mononuclear cells to induce neural stem cells by Sendai virus infection, differentiation of iNSCs into dopaminergic neurons, transplantation of DA precursors into the unilaterally-lesioned Parkinson's disease mouse models, and evaluation of the safety and efficacy of iNSC-derived DA precursors for PD treatment.

Abstract

Parkinson's disease (PD) is caused by degeneration of dopaminergic (DA) neurons at the substantia nigra pars compacta (SNpc) in the ventral mesencephalon (VM). Cell replacement therapy holds great promise for treatment of PD. Recently, induced neural stem cells (iNSCs) have emerged as a potential candidate for cell replacement therapy due to the reduced risk of tumor formation and the plasticity to give rise to region-specific neurons and glia. iNSCs can be reprogrammed from autologous somatic cellular sources, such as fibroblasts, peripheral blood mononuclear cells (PBMNCs) and various other types of cells. Compared with other types of somatic cells, PBMNCs are an appealing starter cell type because of the ease to access and expand in culture. Sendai virus (SeV), an RNA non-integrative virus, encoding reprogramming factors including human OCT3/4, SOX2, KLF4 and c-MYC, has a negative-sense, single-stranded, non-segmented genome that does not integrate into host genome, but only replicates in the cytoplasm of infected cells, offering an efficient and safe vehicle for reprogramming. In this study, we describe a protocol in which iNSCs are obtained by reprogramming PBMNCs, and differentiated into specialized VM DA neurons by a two-stage method. Then DA precursors are transplanted into unilaterally 6-hyroxydopamine (6-OHDA)-lesioned PD mouse models to evaluate the safety and efficacy for treatment of PD. This method provides a platform to investigate the functions and therapeutic effects of patient-specific DA neural cells in vitro and in vivo.

Introduction

Parkinson's disease (PD) is a common neurodegenerative disorder, caused by degeneration of dopaminergic (DA) neurons at the substantia nigra pars compacta (SNpc) in the ventral mesencephalon (VM), with a prevalence of more than 1% in population over 60 years of age^1,2. Over the past decade, cell therapy, aimed at either replacing the degenerative or damaged cells, or nourishing the microenvironment around the degenerating neurons, has shown potential in treatment of PD³. Meanwhile, reprogramming technology has made significant progress⁴, which provides a promising cellular source for replacement therapy. Human induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) have been proven to be able to differentiate into DA neural cells, which could survive, maturate, and improve the motor functions when grafted into rat and non-human primate PD models^5,6,7,8. iPSCs represent a milestone in cellular reprogramming technologies and have a great potential in cell transplantation; however, there is still a concern about the risk of tumor formation from the incompletely differentiated cells. An alternative cellular source for cell transplantation is lineage-committed adult stem cells obtained through direct reprogramming, such as induced neural stem cells (iNSCs), which can be derived from the unstable intermediates, bypassing the pluripotency stage^9,10,11.

Both iPSCs and iNSCs can be reprogrammed from autologous cellular sources, such as fibroblasts, peripheral blood mononuclear cells (PBMNCs) and various other types of cells^12,13,14, thus reducing the immunogenicity of transplanted cells to a great degree. Moreover, compared with iPSCs, iNSCs are inherent with reduced risk of tumor formation and lineage-committed plasticity, only able to differentiate into neurons and glia¹¹. In the initial studies, human or mouse iPSCs and iNSCs were generated from fibroblasts obtained from skin biopsies, which is an invasive procedure^14,15. With this respect, PBMNCs are an appealing starter cell source because of the less invasive sampling process, and the ease to obtain large numbers of cells within a short period of expansion time¹⁶. Initial reprogramming studies employed integrative delivery systems, such as lentiviral or retroviral vectors, which are efficient and easy to implement in many types of cells¹⁷; however, these delivery systems may cause mutations and reactivation of residual transgenes, which present safety issues for clinical therapeutic purposes¹². Sendai virus (SeV) is a non-integrative RNA virus with a negative-sense, single-stranded genome that does not integrate into host genome, but only replicates in the cytoplasm of infected cells, offering an efficient and safe vehicle for reprogramming^18,19. Recombinant SeV vectors are available that contain reprogramming factors including human OCT3/4, SOX2, KLF4 and c-MYC in their open reading frames. In addition, SeV viral vectors can be further improved by introducing temperature-sensitive mutations, so that they could be rapidly removed when the culture temperature is raised to 39 °C²⁰. In this article, we describe a protocol to reprogram PBMNCs to iNSCs using the SeV system.

Many studies have reported derivation of DA neurons from human ESCs or iPSCs using various methods^6,8,21. However, there is a shortage of protocols describing the differentiation of DA neurons from iNSCs in details. In this protocol, we will describe the efficient generation of DA neurons from iNSCs using a two-stage method. The DA neuronal precursors can be transplanted into the striatum of PD mouse models for safety and efficacy evaluations. This article will present a detailed protocol that covers various stages from generation of induced neural stem cells by Sendai virus, differentiation of iNSCs into DA neurons, establishment of mouse PD models, to transplantation of DA precursors into the striatum of the PD models. Using this protocol, one can generate iNSCs from patients and healthy donors and derive DA neurons that are safe, standardizable, scalable and homogeneous for cell transplantation purposes, or for modeling PD in a dish and investigation of the mechanisms underlying disease onset and development.

Protocol

All procedures must follow the guidelines of institutional human research ethics committee. Informed consent must be obtained from patients or healthy volunteers before blood collection. This protocol was approved by the institution's human research ethics committee and was performed according to the institution's guidelines for care and use of animals.

1. Collection, isolation and expansion of PBMNCs

1. Collection of PBMNCs
   1. Collect 10-20 mL of donor’s peripheral venous blood by venipuncture with a sodium heparin preservative vial.
      NOTE: Blood samples should be stored or shipped at room temperature (RT). Process the blood samples within 24 h.
2. Preparation of culture medium
   1. Prepare serum free medium (SFM) by combining the following components: 245 mL of Iscove's modified Dulbecco's medium (IMDM), 240 mL of Ham’s F-12, 5 mL of insulin-transferrin-selenium-X supplement (ITS-X), 5 mL of 100x glutamine stock solution (Table of Materials), 5 mL of chemically defined lipid concentrate, 2.5 g of fetal bovine serum, 0.025 g of ascorbic acid and 9 μL of 1-thioglycerol. Filter the medium and store it at 4 °C.
      CAUTION: Ascorbic acid and 1-thioglycerol are toxic by skin contact and inhalation.
   2. To prepare mononuclear cell (MNC) medium, supplement the SFM medium with 10 ng/mL human interleukin 3 (IL-3), 2 U/mL erythropoietin (EPO), 100 ng/mL human stem cell factor (SCF), 40 ng/mL human insulin-like growth factor 1 (IGF-1), 100 μg/mL holo-transferrin and 1 μM dexamethasone. Filter the medium and store it at 4 °C.
      NOTE: Prepare the medium immediately before use.
3. Isolation of PBMNCs
   1. Ultraviolet-sterilize a clean bench prior to use. Sterilize all surfaces and equipment with 75% alcohol. Sterilize all tips by using an autoclave.
   2. Transfer the peripheral blood (PB) into a 50 mL conical tube and dilute the PB with an equal volume of sterile Dulbecco's phosphate-buffered saline (D-PBS).
   3. Prepare 15 mL of sterilized density gradient medium (Tables of Materials) in another 50 mL conical tube.
      NOTE: Keep the density gradient medium and PB at RT to allow for better isolation of PBMNCs.
   4. Tilt the conical tube containing the density gradient medium at a 45° angle, and then slowly and carefully lay 30 mL of diluted PB onto the density gradient medium.
      NOTE: Take care and allow the PB to slowly run down the side of the conical tube onto the density gradient medium layer. Red blood cells will deposit to the bottom of the tube. Tilt the tube carefully to minimize disruption of the layer interface.
   5. Centrifuge the tubes at 800 x g for 15 min at RT with the centrifuge brake set at "off" position. Aspirate the yellow, upper plasma layer and discard it. Then transfer the white cloudy thin film layer containing MNCs with a 10 mL pipette to a new 50 mL conical tube.
      NOTE: Switching centrifuge brake off is important for the isolation of MNCs.
   6. Add 30 mL of D-PBS to the tube with MNCs and centrifuge at 600 x g for 10 min at 4 °C. Discard the supernatant, and then add 45 mL of D-PBS to re-suspend the cells. Centrifuge at 400 x g for 10 min at 4 °C.
      NOTE: The centrifuge brake should be switched on for this and the following centrifugation steps. As the cell pellets are dense, add 1-2 mL of D-PBS to gently re-suspend the pellets, and then add D-PBS to 45 mL.
   7. Discard the supernatant and re-suspend the cells with 5 mL of D-PBS and count the live cells with the trypan blue exclusion method.
   8. After setting aside the MNCs needed for expansion, freeze the remaining cells for future use.
      NOTE: At least 5 x 10⁶ MNCs can be frozen in one vial with 1 mL of freezing medium (Table of Materials). The protocol can be paused here.
4. Expansion of MNCs
   1. On day -14, seed MNCs at a density of 2-3 x 10⁶ cells per milliliter in one well of six-well plates with 1.5 mL of pre-warmed (37 °C) MNC medium. Incubate at 37 °C, 5% CO₂ for 2 days.
   2. On day -11, collect the cells and medium with a sterilized pipette and transfer to a new 15 mL conical tube. Centrifuge the cells at 250 x g for 5 min at RT. Discard the supernatant and re-suspend the cells in 1 mL of pre-warmed (37 °C) MNC medium.
   3. Count the viable cells with trypan blue. Seed the MNCs at a density of 1 x 10⁶ cells per milliliter in pre-warmed MNC medium and incubate at 37 °C, 5% CO₂ for 3 days.
      NOTE: It is expected that the total number of cells may decrease on day -11.
   4. On day -8, repeat steps 1.4.2-1.4.3 and culture the cells for 3 days.
   5. On day -4, repeat steps 1.4.2-1.4.3 and culture the cells for 3 days.
      NOTE: After 14 days of culture, an equal or greater number of MNCs should remain in the culture.

2. Reprogramming of PBMNCs to iNSCs by SeV Infection

1. Preparation of solution and culture medium
   1. Prepare a poly-D-lysine (PDL) stock solution by dissolving 100 mg of PDL with 100 mL of H₂O to a concentration of 1 mg/mL. Store at -20 °C in 1 mL aliquots.
   2. Prepare an insulin stock solution by dissolving 100 mg of insulin in 20 mL of 0.01 N HCl to a concentration of 5 mg/mL. Store at -20 °C in 1 mL aliquots.
   3. To prepare 200 mL of iNSC basal medium, combine 96 mL of DMEM-F12 and 96 mL of basic medium (Table of Materials) with 2 mL of 100x glutamine stock solution, 2 mL of nonessential amino acid (NEAA), 2 mL of N2 supplement and 2 mL of B27 supplement. Add 10 ng/mL recombinant human leukemia inhibitory factor, 3 μM CHIR99021 and 2 μM SB431542 prior to use. Filter the medium and store it at 4 °C.
      NOTE: Use the medium within 2 weeks. Add recombinant human leukemia inhibitory factor, CHIR99021 and SB431542 immediately before use.
2. Reprogramming of PBMNCs to iNSCs by SeV Infection
   1. Ultraviolet-sterilize a clean bench prior to use. Sterilize all surfaces and equipment with 75% alcohol. Sterilize all tips using an autoclave.
   2. On day 0, collect the cells in MNC medium and transfer to a 15 mL conical tube. Centrifuge the cells at 200 x g for 5 min. Aspirate the supernatant and re-suspend the cells with 1 mL of pre-warmed MNC medium.
   3. Count the viable cells with trypan blue. Re-suspend the cells with pre-warmed (37 °C) MNC medium to a concentration of 2 x 10⁵ cells per well in 24-well plates.
   4. After removing the SeV tubes from -80 °C storage, thaw the tubes containing SeV in 37 °C water bath for 5-10 s, and then allow them to thaw at RT. Once thawed, place them on ice immediately.
   5. Add the SeV encoding human Klf4, Oct3/4, SOX2 and c-MyC to the wells, at a multiplicity of infection (MOI) of 10. Centrifuge cells with plates at 1,000 x g for 30 min to facilitate the attachment of cells. Leave the cells and supernatant in the plates. Place the plates in the incubator at 37 °C, 5% CO₂.
      CAUTION: All procedures involving SeV must be performed in a safety cabinet, and all tips and tubes should be treated with ethanol or bleach before disposal.
   6. On day 1, transfer the medium and cells to a 15 mL centrifuge tube. Rinse the well with 1 mL of MNC medium. Centrifuge the cell suspension at 200 x g for 5 min. Aspirate the supernatant and re-suspend the cells with 500 μL of fresh pre-warmed MNC medium in 24-well plates.
      NOTE: Use a low attachment 24-well plate to prevent attachment of any cells before plating on PDL/laminin.
   7. On day 2, dilute 1 mL of 1 mg/mL PDL with 19 mL of D-PBS to a concentration of 50 μg/mL. Coat 6-well plates with 50 μg/mL PDL for at least 2 h at RT.
   8. Dilute 200 μL of 0.5 mg/mL laminin with 20 mL of D-PBS to a concentration of 5 µg/mL. Aspirate PDL in the 6-well plates, and dry on the vertical clean bench.
   9. Coat 6-well plates with 5 μg/mL laminin and incubate for 4-6 h at 37 °C. Wash with D-PBS before use.
   10. On day 3, plate the transduced cells obtained in step 2.2.6 in iNSC medium on PDL/laminin-coated 6-well plates.
       NOTE: Move the plates gently if needed after the cells are placed on PDL/laminin-coated plates, trying not to disturb the attachment of the cells.
   11. On day 5, add 1 mL of pre-warmed (37 °C) iNSC medium in each well in 6-well plates gently.
       NOTE: It is expected that the cells will undergo drastic death (>60%).
   12. On day 7, add 1 mL of pre-warmed (37 °C) iNSC medium in each well in 6-well plates gently.
   13. From day 9 to day 28, replace spent medium with fresh pre-warmed (37 °C) iNSC medium every day. Monitor the emergence of iNSC colonies. Pick and transfer iNSC clones for expansion in about 2-3 weeks. Pick up colonies with appropriate morphology using burned glass pipettes, excluding any possibly contaminating cells, and aspirate the colonies with 200 μL tips.
       NOTE: The characterized iNSCs can be frozen for future use with 2-5 colonies in one vial. The freezing medium includes serum free basal medium (Table of Materials) and dimethyl sulfoxide mixed at a ratio of 9:1, which should be prepared immediately before use. The protocol can be paused here.

3. Differentiation of iNSCs to dopaminergic neurons

1. Preparation of solution and culture medium
   1. Prepare 200 mL of iNSC differentiation basal medium by combining 192 mL of DMEM-F12 with 2 mL of 100x glutamine stock solution, 2 mL of NEAA, 2 mL of N2 supplement and 2 mL of B27 supplement.
      NOTE: Use the medium within 2 weeks.
   2. Prepare iNSC differentiation stage I medium by supplementing the iNSC differentiation basal medium with 1 μM SAG1 and 100 ng /mL FGF8b.
      NOTE: Use the medium within 2 weeks.
   3. Prepare iNSC differentiation stage II medium by supplementing the iNSC differentiation basal medium with 0.5 mM cyclic adenosine monophosphate (cAMP), 0.2 mM ascorbic acid, 10 μM DAPT, 10 ng/mL brain derived neurotrophic factor (BDNF), 10 ng/mL glial derived neutrophic factor (GDNF) and 1 ng/mL transforming growth factor βIII (TGF-βIII).
      NOTE: Use the medium within 2 weeks.
2. Coating the culture dishes
   1. Ultraviolet-sterilize a clean bench prior to use. Sterilize all surfaces and equipment with 75% alcohol. Sterilize all tips using an autoclave.
   2. For PDL coating, at least one day before re-plating the cells, dilute 1 mL of 1 mg/mL PDL with 19 mL of D-PBS to a concentration of 50 μg/mL. Coat 12 mm glass coverslips that have been sterilized with 75% alcohol in the 24-well plates with 50 μg/mL PDL at RT for at least 2 h.
   3. For laminin coating, dilute 200 μL of 0.5 mg/mL laminin with 20 mL of D-PBS to a concentration of 5 μg/mL. Aspirate PDL and dry the wells in the clean bench. Coat the 12 mm coverslips with 5 μg/mL laminin and incubate for 4-6 h at 37 °C. Wash with D-PBS before use.
3. Passage cells for differentiation.
   1. When the confluence of cultured iNSCs reaches 70-90%, aspirate medium from the culture plate, and add 1 mL of D-PBS to wash the cells. Add 1 mL of pre-warmed (37 °C) cell dissociation reagent (Table of Materials) per well and incubate at 37 °C for 3 min to dissociate the cells.
   2. After incubation for 3 min, the cells have become semi-floating; add 3 mL of pre-warmed (37 °C) DMEM-F12 medium per well, and pipette cells up and down to dissociate cell pellets into single cells.
   3. Transfer cells into a 15 mL conical tube, and centrifuge at 250 x g for 3 min. Aspirate the supernatant, re-suspend the cells with appropriate volume of pre-warmed (37 °C) iNSC medium according to the number of cells.
   4. Count the cells using the trypan blue exclusion method. Plate 5 x 10³ cells per 12 mm glass coverslip in 24-well plates and incubate at 37 °C, 5% CO₂.
4. Differentiate iNSCs into dopaminergic neurons.
   1. Start differentiation 24 h after re-plating the cells onto PDL/laminin-coated coverslips. Aspirate culture medium, wash cells once with D-PBS, and then add 600 μL of pre-warmed differentiation stage I medium per well in 24-well plates and incubate at 37 °C, 5% CO₂.
   2. Change medium every day from day 1 to day 10 during the first stage of differentiation.
   3. On day 10, aspirate the culture medium, and wash cells once with D-PBS. Add 600 μL of pre-warmed (37 °C) differentiation stage II medium per well in 24-well plates and incubate at 37 °C, 5% CO₂.
   4. Change medium every other day from day 11 to day 25 during the second stage of differentiation. The differentiated cells can be fixed by paraformaldehyde at different time points for analysis.
   5. For immunofluorescent staining, wash the cells with D-PBS three times gently at chosen time points within differentiation day 11 to 25.
   6. Pipette 300 μL of nonionic surfactant (Table of Materials) into 100 mL of PBS to make a 0.3% nonionic surfactant in PBS.
      CAUTION: Nonionic surfactant is toxic by skin contact and inhalation.
   7. Fix the cells with 4% paraformaldehyde for 10 min at RT. Then wash with 0.3%  in PBS three times.
      CAUTION: Paraformaldehyde is toxic by skin contact and inhalation.
   8. Block the cells by 3% donkey serum for 2 h at RT.
   9. Dilute the primary antibody in 1% donkey serum at an appropriate concentration and gently triturate to mix. Add 300 μL of the primary antibody solution to each well of the 24-well plate. Incubate the cells at 4 °C overnight. Wash the cells with 0.3% nonionic surfactant in PBS three times.
   10. Dilute the secondary antibody in 1% donkey serum at an appropriate concentration and gently triturate to mix. Add 300 μL of the secondary antibody solution to each well of the 24-well plate. Incubate the cells at RT for 2 h, protected from light.
   11. Wash the cells with 0.3% nonionic surfactant in PBS three times. Dilute 4',6-diamidino-2-phenylindole (DAPI) with PBS with 1:500 dilution. Incubate the cells in each well of the 24-well plate with 300 μL of diluted DAPI for 15 min at RT, protected from light. Wash the cells with 0.3% nonionic surfactant in PBS three times.
   12. Gently take out the coverslips from the wells of plates with forceps. Dry in dark overnight at RT. Mount under a fluorescence microscope.

4. Establishment of unilateral 6-hyroxydopamine (6-OHDA)-lesioned PD mouse models

1. To generate PD mouse models for cell transplantation, use adult male SCID-beige mice weighing 20-25 g for 6-OHDA injection.
2. Preparation of drugs for surgery
   1. Prepare a 0.2% ascorbic acid solution by dissolving 0.2 g of ascorbic acid into 100 mL of sterilized saline (0.9%) and store at -80 °C until use. On the day of surgery, dilute 0.2% ascorbic acid solution by 10 times to obtain a 0.02% ascorbic acid solution.
      NOTE: Ascorbic acid is added to prevent oxidation of 6-OHDA to an inactive form.
   2. To prepare a 6-OHDA solution, weigh appropriate amount of 6-OHDA into a sterilized 1 mL tube, and then add some volume of 0.02% ascorbic acid to make a 5 μg/μL 6-OHDA solution. Vortex the mixture until it is dissolved. Place the 6-OHDA on ice until use.
      NOTE: 6-OHDA is temperature and light sensitive. Be careful to protect the solution from light and keep it on ice before use.
3. Prepare sterilized surgical equipment by autoclaving before surgery. Clean all equipment and surface areas with ethanol when setting up the stereotaxic frame. Set up a mouse recovery cage under a heating lamp.
4. Conduct surgery to establish unilateral 6-OHDA-lesioned mouse models.
   1. Weigh each mouse, record the weight and calculate the amount of drug that needs to be administered. Each mouse receives 0.5 mg/kg atropine 20 min prior to operations. Anesthetize the mouse with 80 mg/kg ketamine and 10 mg/kg xylazine.
   2. Administer 0.5 mg/kg atropine by intraperitoneal injection.
   3. Anesthetize the mouse with 80 mg/kg ketamine and 10 mg/kg xylazine by intraperitoneal injection 20 min after administration of atropine.
   4. Put the mouse in a closed chamber. After 3-5 min, the mouse will be deeply anesthetized without response to hind leg pinch.
      NOTE: It is expected that the mouse that has received anesthesia would experience an excitation period.
   5. Shave the head of mouse and apply erythromycin eye ointment on the eyes of mouse for protection from developing corneal ulcers.
   6. Place the mouse on the stereotaxic apparatus. Fix the mouse with incisor bars firstly. Insert the ear cups correctly to make the mouse head in a flat and secure position.
   7. Sterilize the head of the mouse with povidone iodine and isopropyl alcohol. Cut a sagittal incision (~1.5 cm) on the head skin with a scalpel blade, and expose the skull. Adjust the incisor bar and ear bars to reduce the height difference between bregma and lambda to less than 0.1 mm.
      NOTE: The mouse bregma is located at the intersection of coronal and sagittal sutures, and lambda is at the intersection of lambdoid and sagittal sutures.
   8. Slowly move and lower the tip of the needle towards bregma and treat the bregma as a zero point. Move the tip to a position with coordinates of A/P +0.5 mm, M/L -2.1 mm relative to bregma. Retract the tip and mark the point. Burr a little hole into the skull.
   9. Extract 2 μL of 5 μg/μL 6-OHDA solution into the microsyringe (Table of Materials). Return the needle to the point marked, and insert the needle to D/V -3.2 mm.
   10. Inject 2 μL of 5 μg/μL 6-OHDA solution (10 μg total) at a rate of 1 μL/min. After injection of 6-OHDA is completed, leave the needle in place for another 5 min. Then retract the injection needle slowly.
   11. Close the incision with sutures and apply erythromycin eye ointment on the eyes of mouse. Deliver 0.5 mL saline subcutaneously to prevent dehydration, and apply an antibiotic ointment directly on the sutured skin.
   12. Remove the mouse from stereotaxic apparatus and put it in the recovery cage. Put the mouse back and allow access to food and water until it regains consciousness. Treat the mouse with analgesic in drinking water daily post-surgery for 2-3 days, and a recommended dosage of Ibuprofen is 0.03 mg/g of body weight per day.
   13. Inspect the mouse daily post-surgery.

5. Behavioral assessment after unilateral 6-OHDA lesioning

1. Two to three weeks following surgery, conduct behavioral assessment to estimate PD symptoms. Weigh each mouse, record their weight and calculate the amount of drug that should be administered (0.5 mg/kg apomorphine prior to assessment).
2. Administer 0.5 mg/kg apomorphine by subcutaneous injection before assessment and place the mouse in a glass cylinder.
3. After a 5 min habituation period, count the number of contralateral and ipsilateral rotations relative to the lesion side per minute and record their activity with a video camera.
4. Mice with contralateral minus ipsilateral rotations >7 rpm/min are considered successfully lesioned and selected as candidates for cell transplantation experiments. Return the mice to the housing cages after a 30-min rest.
   NOTE: If the mouse were successfully lesioned, 6-OHDA injected mouse will show a greater bias in turning towards contralateral side since the DA agonist activates the supersensitive denervated striatum of the lesioned side predominantly.
5. Conduct the behavioral assessment one week before and 2, 4, 6, 8, 12, 16 weeks after cell transplantation.

6. Cell transplantation of DA precursors

1. Prepare cell suspension for transplantation. For cell engraftment, suspend 2 x 10⁵ DA precursors mixed by D10 and D13 DA precursors at a ratio of 1:7 in 4 μL of 5 g L^-1 glucose in  balanced salt solution (Table of Materials) of transplantation buffer.
2. Perform cell transplantation surgery following the procedures described in section 4.4, except that 6-OHDA is replaced by DA precursor cell suspension or buffer.
3. Perform the behavioral assessment 2, 4, 6, 8, 12, 16 weeks after cell transplantation of DA precursors following the procedures described in section 5. Count the number of apomorphine-induced contralateral rotations relative to the lesion side per minute and record their activity with a video camera.
   NOTE: After transplantation, a reduced rate of contralateral rotations suggests an improved motor function.
4. At 4, 8 ,12, and 16 weeks after cell transplantation, perfuse the mouse under deep anesthesia with 4% paraformaldehyde until the body of mouse becomes stiff and the liver of mouse becomes pale.
5. Separate the brain of mouse gently and put the brain in 4% paraformaldehyde at 4 °C overnight.
6. On the second day, put the brain in 30% sucrose for dehydration until the brain sinks to the bottom.
7. Slice the brains at 40 μm thickness by using a freezing microtome.
8. Perform immunostaining as previously described in steps 3.4.5-3.4.12.

Results

Here, we report a protocol that covers different stages of iNSC-DA cell therapy to treat PD models. Firstly, PBMNCs were isolated and expanded, and reprogrammed into iNSCs by SeV infection. A schematic representation of the procedures with PBMNC expansion and iNSC induction is shown in Figure 1. On day -14, PBMNCs were isolated by using a density gradient medium (Table of Materials). Before centrifugation, blood diluted with PBS and the density gradient medium were separated...

Discussion

Here we presented a protocol that covered different stages of iNSC-DA cell therapy for PD models. Critical aspects of this protocol include: (1) isolation and expansion of PBMNCs and reprogramming of PBMNCs into iNSCs by SeV infection, (2) differentiation of iNSCs to DA neurons, (3) establishment of unilateral 6-OHDA-lesioned PD mouse models and behavioral assessment, and (4) cell transplantation of DA precursors and behavioral assessment.

In this protocol, the first part involves collecting a...

Materials

Name	Company	Catalog Number	Comments
15-ml conical tube	Corning	430052
1-Thioglycerol	Sigma-Aldrich	M6145	Toxic for inhalation and skin contact
24-well plate	Corning	3337
50-ml conical tube	Corning	430828
6-OHDA	Sigma-Aldrich	H4381
6-well plate	Corning	3516
Accutase	Invitrogen	A11105-01	Cell dissociation reagent
Apomorphine	Sigma-Aldrich	A4393
Ascorbic acid	Sigma-Aldrich	A92902	Toxic with skin contact
B27 supplement	Invitrogen	17504044
BDNF	Peprotech	450-02	Brain derived neurotrophic factor
Blood collection tubes containing sodium heparin	BD	367871
BSA	yisheng	36106es60	Fetal bovine serum
cAMP	Sigma-Aldrich	D0627	Dibutyryladenosine cyclic monophosphate
CellBanker 2	ZENOAQ	100ml	Used as freezing medium for PBMNCs
Chemically defined lipid concentrate	Invitrogen	11905031
CHIR99021	Gene Operation	04-0004
Coverslip	Fisher	25*25-2
DAPI	Sigma-Aldrich	D8417-10mg
DAPT	Sigma-Aldrich	D5942
Dexamethasone	Sigma-Aldrich	D2915-100MG
DMEM-F12	Gibco	11330
DMEM-F12	Gibco	11320
Donkey serum	Jackson	017-000-121
EPO	Peprotech	100-64-50UG	Human Erythropoietin
FGF8b	Peprotech	100-25
Ficoll-Paque Premium	GE Healthcare	17-5442-02	P=1.077, density gradient medium
GDNF	Peprotech	450-10	Glial derived neurotrophic factor
GlutaMAX	Invitrogen	21051024	100 × Glutamine stock solution
Ham's-F12	Gibco	11765-054
HBSS	Invitrogen	14175079	Balanced salt solution
Human leukemia inhibitory factor	Millpore	LIF1010
Human recombinant SCF	Peprotech	300-07-100UG
IGF-1	Peprotech	100-11-100UG	Human insulin-like growth factor
IL-3	Peprotech	200-03-10UG	Human interleukin 3
IMDM	Gibco	215056-023	Iscove's modified Dulbecco's medium
Insulin	Roche	12585014
ITS-X	Invitrogen	51500-056	Insulin-transferrin-selenium-X supplement
Knockout serum replacement	Gibco	10828028	Serum free basal medium
Laminin	Roche	11243217001
Microsyringe	Hamilton	7653-01
N2 supplement	Invitrogen	17502048
NEAA	Invitrogen	11140050	Non-essential amino acid
Neurobasal	Gibco	10888	Basic medium
PDL	Sigma-Aldrich	P7280	Poly-D-lysine
SAG1	Enzo	ALX-270-426-M01
SB431542	Gene Operation	04-0010-10mg	Store from light at -20?
Sendai virus	Life Technologies	MAN0009378
Sucrose	baiaoshengke
TGFβ?	Peprotech	100-36E	Transforming growth factor  β?
Transferrin	R&D Systems	2914-HT-100G
Triton X 100	baiaoshengke		Nonionic surfactant
Trypan blue	Gibco	T10282
Xylazine	Sigma-Aldrich	X1126